Chemistry:Necitumumab
From HandWiki
Short description: Recombinant human monoclonal antibody
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | EGFR |
| Clinical data | |
| Trade names | Portrazza |
| AHFS/Drugs.com | Multum Consumer Information |
| License data |
|
| Routes of administration | Intravenous infusion |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | ~14 days |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6436H9958N1702O2020S42 |
| Molar mass | 144844.87 g·mol−1 |
  (what is this?) (verify) | |
Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic, which is manufactured by Eli Lilly. It binds to the epidermal growth factor receptor (EGFR).[1] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).[2][3][4] It was counterproductive in non-squamous non-small-cell lung carcinoma.[4][5]
References
- ↑ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
- ↑ "Necitumumab (Portrazza) Approved for Lung Cancer in US". Medscape.com. 2015-11-22. http://www.medscape.com/viewarticle/854952?nlid=91969_3663&src=wnl_edit_newsal&uac=78316PX&impID=899999&faf=1.
- ↑ "Necitumumab". Approved Drugs. U.S. Food and Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm474278.htm.
- ↑ 4.0 4.1 "Portrazza: Highlights of Prescribing Information". 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf.
- ↑ "Necitumumab Fails in NSCLC". MedScape. 3 March 2015. http://www.medscape.com/viewarticle/840768.
 |  |
